Safety and Preliminary Efficacy of Recombinant Activated Factor VII in Subjects With Traumatic Brain Injury
Status:
Completed
Trial end date:
2006-05-01
Target enrollment:
Participant gender:
Summary
This trial is conducted in Asia, Europe, Middle East, and North America. The primary
objective of the trial is to evaluate the safety of Recombinant Activated Factor VII in
patients with brain contusions. The secondary objective of the trial is to evaluate the
preliminary efficacy of Recombinant Activated Factor VII in preventing early haemorrhagic
progression in contusive brain injury.